SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2806)6/24/2011 1:51:11 PM
From: fred hayes  Respond to of 3661
 
Hi Tuck. I think I had drrx in the charity portfolio too, will have to go look. Anyway,I didn't expect approval today because PFE as much as said they expected delay due to mfg issue and some fda unsettled policy on this kinda abuse prevention drug. They didn't specify the mfg problem. I never expected this kind of drop on the crl. I can't find any specifics on the problem but as far as I know Remoxy is just fine. Fully expect subsequent approval and that problems are minor. But who knows for sure?

fred



To: tuck who wrote (2806)1/5/2012 6:23:02 PM
From: tuck  Respond to of 3661
 
DuRect's (DRRX) other advanced candidate, also for pain, flubs P3, and the stock is off 47% after hours, well into penny stock status. Dunno if there's much hope for regulatory salvation; I have seen no sign that the issues raised in the CRL are being addressed with a response imminent. Even if they get their oxycodone formulation through, that market isn't without competitors. Haven't looked in quite a while to see if we're looking at major dilution to stay afloat.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News